Exact Mass: 617.3543652

Lolicine B

C38H51NO6 (617.3716185999999)

Neuromedin N

C32H51N5O7 (617.3788296)

Neuromedin N is a neuropeptide derived from the same precursor polypeptide as neurotensin, and with similar but subtly distinct expression and effects. [HMDB] Neuromedin N is a neuropeptide derived from the same precursor polypeptide as neurotensin, and with similar but subtly distinct expression and effects.

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C30H52NO10P (617.3328662)

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of Leukotriene B4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C30H52NO10P (617.3328662)

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0), in particular, consists of one chain of one Leukotriene B4 at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C30H52NO10P (617.3328662)

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C30H52NO10P (617.3328662)

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0), in particular, consists of one chain of one 5(S),15(S)-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C30H52NO10P (617.3328662)

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-Dihydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C30H52NO10P (617.3328662)

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0), in particular, consists of one chain of one 5,6-Dihydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

Spiroidesin

C35H43N3O7 (617.3100848)

Ramosine B

C35H47N5O5 (617.3577012)

veralosine

C35H55NO8 (617.392747)

Lotusine C

C35H47N5O5 (617.3577012)

Mauritine B

C35H47N5O5 (617.3577012)

6-benzylamino-9-(glucosylribosyl)purine

C30H43N5O9 (617.3060628000001)

shearinine C

C37H47NO7 (617.3352351999999)

1-(N-methyl-L-phenylalanyl)-L-proline (4S)-7t-isobutyl-3t-isopropyl-5,8-dioxo-2-oxa-6,9-diaza-1(1,4)-benzena-cycloundecaphan-10c-en-4r-ylamide|Lasiodin B|Lasiodin-B|Lasiodine B|lasiodine-B

C35H47N5O5 (617.3577012)

penitremone B

C37H47NO7 (617.3352351999999)

8-Deacetylyunaconitine

C33H47NO10 (617.3199802)

C38H51NO6

C38H51NO6 (617.3716185999999)

Hypaconitine

C33H47NO10 (617.3199802)

Leu Ser Leu Glu Glu

C27H47N5O11 (617.3271912)

Glu Glu Leu Ile Thr

C27H47N5O11 (617.3271912)

Ala Arg Trp Trp

C31H39N9O5 (617.3074003999999)

Ala Trp Arg Trp

C31H39N9O5 (617.3074003999999)

Ala Trp Trp Arg

C31H39N9O5 (617.3074003999999)

Glu Lys Arg Trp

C28H43N9O7 (617.3285288)

Glu Lys Trp Arg

C28H43N9O7 (617.3285288)

Glu Arg Lys Trp

C28H43N9O7 (617.3285288)

Glu Arg Trp Lys

C28H43N9O7 (617.3285288)

Glu Trp Lys Arg

C28H43N9O7 (617.3285288)

Glu Trp Arg Lys

C28H43N9O7 (617.3285288)

Lys Glu Arg Trp

C28H43N9O7 (617.3285288)

Lys Glu Trp Arg

C28H43N9O7 (617.3285288)

Lys Arg Glu Trp

C28H43N9O7 (617.3285288)

Lys Arg Trp Glu

C28H43N9O7 (617.3285288)

Lys Val Trp Trp

C33H43N7O5 (617.3325507999999)

Lys Trp Glu Arg

C28H43N9O7 (617.3285288)

Lys Trp Arg Glu

C28H43N9O7 (617.3285288)

Lys Trp Val Trp

C33H43N7O5 (617.3325507999999)

Lys Trp Trp Val

C33H43N7O5 (617.3325507999999)

Met Arg Arg Arg

C23H47N13O5S (617.3543652)

Arg Ala Trp Trp

C31H39N9O5 (617.3074003999999)

Arg Glu Lys Trp

C28H43N9O7 (617.3285288)

Arg Glu Trp Lys

C28H43N9O7 (617.3285288)

Arg Lys Glu Trp

C28H43N9O7 (617.3285288)

Arg Lys Trp Glu

C28H43N9O7 (617.3285288)

Arg Met Arg Arg

C23H47N13O5S (617.3543652)

Arg Arg Met Arg

C23H47N13O5S (617.3543652)

Arg Arg Arg Met

C23H47N13O5S (617.3543652)

Arg Arg Thr Trp

C27H43N11O6 (617.3397617999999)

Arg Arg Trp Thr

C27H43N11O6 (617.3397617999999)

Arg Thr Arg Trp

C27H43N11O6 (617.3397617999999)

Arg Thr Trp Arg

C27H43N11O6 (617.3397617999999)

Arg Trp Ala Trp

C31H39N9O5 (617.3074003999999)

Arg Trp Glu Lys

C28H43N9O7 (617.3285288)

Arg Trp Lys Glu

C28H43N9O7 (617.3285288)

Arg Trp Arg Thr

C27H43N11O6 (617.3397617999999)

Arg Trp Thr Arg

C27H43N11O6 (617.3397617999999)

Arg Trp Trp Ala

C31H39N9O5 (617.3074003999999)

Thr Arg Arg Trp

C27H43N11O6 (617.3397617999999)

Thr Arg Trp Arg

C27H43N11O6 (617.3397617999999)

Thr Trp Arg Arg

C27H43N11O6 (617.3397617999999)

Val Lys Trp Trp

C33H43N7O5 (617.3325507999999)

Val Trp Lys Trp

C33H43N7O5 (617.3325507999999)

Val Trp Trp Lys

C33H43N7O5 (617.3325507999999)

Trp Ala Arg Trp

C31H39N9O5 (617.3074003999999)

Trp Ala Trp Arg

C31H39N9O5 (617.3074003999999)

Trp Glu Lys Arg

C28H43N9O7 (617.3285288)

Trp Glu Arg Lys

C28H43N9O7 (617.3285288)

Trp Lys Glu Arg

C28H43N9O7 (617.3285288)

Trp Lys Arg Glu

C28H43N9O7 (617.3285288)

Trp Lys Val Trp

C33H43N7O5 (617.3325507999999)

Trp Lys Trp Val

C33H43N7O5 (617.3325507999999)

Trp Arg Ala Trp

C31H39N9O5 (617.3074003999999)

Trp Arg Glu Lys

C28H43N9O7 (617.3285288)

Trp Arg Lys Glu

C28H43N9O7 (617.3285288)

Trp Arg Arg Thr

C27H43N11O6 (617.3397617999999)

Trp Arg Thr Arg

C27H43N11O6 (617.3397617999999)

Trp Arg Trp Ala

C31H39N9O5 (617.3074003999999)

Trp Thr Arg Arg

C27H43N11O6 (617.3397617999999)

Trp Val Lys Trp

C33H43N7O5 (617.3325507999999)

Trp Val Trp Lys

C33H43N7O5 (617.3325507999999)

Trp Trp Ala Arg

C31H39N9O5 (617.3074003999999)

Trp Trp Lys Val

C33H43N7O5 (617.3325507999999)

Trp Trp Arg Ala

C31H39N9O5 (617.3074003999999)

Trp Trp Val Lys

C33H43N7O5 (617.3325507999999)

NRESL

C24H43N9O10 (617.3132738)

OKOHA-PE

C30H52NO10P (617.3328662)

PC(2:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))

C30H52NO10P (617.3328662)

PC(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/2:0)

C30H52NO10P (617.3328662)

PC(2:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))

C30H52NO10P (617.3328662)

PC(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/2:0)

C30H52NO10P (617.3328662)

PC(2:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))

C30H52NO10P (617.3328662)

PC(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/2:0)

C30H52NO10P (617.3328662)

WLL-vs

C31H47N5O6S (617.3246882000001)

1-[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

1-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

1-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

1-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(pyridin-4-ylmethyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-3-phenylurea

C35H47N5O5 (617.3577012)

N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(1-naphthalenylamino)-oxomethyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-(4-morpholinyl)propanamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-[oxo(pyridin-4-yl)methyl]amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C34H43N5O6 (617.3213178000001)

Lnaps 6:0/N-18:3

C30H52NO10P (617.3328662)

Lnaps 2:0/N-22:3

C30H52NO10P (617.3328662)

Lnaps 8:0/N-16:3

C30H52NO10P (617.3328662)

Lnaps 16:3/N-8:0

C30H52NO10P (617.3328662)

Lnaps 22:3/N-2:0

C30H52NO10P (617.3328662)

Lnaps 18:3/N-6:0

C30H52NO10P (617.3328662)

Lnaps 4:0/N-20:3

C30H52NO10P (617.3328662)

Lnaps 20:3/N-4:0

C30H52NO10P (617.3328662)

2-amino-3-[[3-butanoyloxy-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3328662)

2-amino-3-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-octanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3328662)

2-amino-3-[[3-hexanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid

C30H52NO10P (617.3328662)

3-[[3-acetyloxy-2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid

C30H52NO10P (617.3328662)

DGCC 25:6

C35H55NO8 (617.392747)

DGTS 25:6;O

C35H55NO8 (617.392747)

PC O-23:4;O2

C31H56NO9P (617.3692496)

PC P-16:0/7:3;O2

C31H56NO9P (617.3692496)

PC P-16:1/7:2;O2

C31H56NO9P (617.3692496)

PC P-18:1/5:2;O2

C31H56NO9P (617.3692496)

PC 14:1/8:3;O2

C30H52NO10P (617.3328662)

PC 16:0/7:3;O

C31H56NO9P (617.3692496)

PC 18:2/5:1;O

C31H56NO9P (617.3692496)

PC 18:3/4:1;O2

C30H52NO10P (617.3328662)

PC 22:4;O2

C30H52NO10P (617.3328662)

PC 23:3;O

C31H56NO9P (617.3692496)

LNAPE 26:3;O

C31H56NO9P (617.3692496)

PE O-25:5;O3

C30H52NO10P (617.3328662)

PE O-26:4;O2

C31H56NO9P (617.3692496)

PE P-18:0/8:3;O2

C31H56NO9P (617.3692496)

PE P-18:1/7:3;O3

C30H52NO10P (617.3328662)

PE P-18:1/8:2;O2

C31H56NO9P (617.3692496)

PE 14:0/12:3;O

C31H56NO9P (617.3692496)

PE 16:0/9:4;O2

C30H52NO10P (617.3328662)

PE 18:0/8:3;O

C31H56NO9P (617.3692496)

PE 18:1/7:3;O2

C30H52NO10P (617.3328662)

PE 18:2/7:2;O2

C30H52NO10P (617.3328662)

PE 18:2/8:1;O

C31H56NO9P (617.3692496)

PE 20:1/6:2;O

C31H56NO9P (617.3692496)

PE 20:3/5:1;O2

C30H52NO10P (617.3328662)

PE 22:2/4:1;O

C31H56NO9P (617.3692496)

PE 26:3;O

C31H56NO9P (617.3692496)

LNAPS 24:3

C30H52NO10P (617.3328662)

PS O-24:4;O

C30H52NO10P (617.3328662)

PS P-16:0/8:3;O

C30H52NO10P (617.3328662)

PS P-18:1/6:2;O

C30H52NO10P (617.3328662)

PS 20:2/4:1

C30H52NO10P (617.3328662)

PS 20:3/4:0

C30H52NO10P (617.3328662)

PS 24:3

C30H52NO10P (617.3328662)

ST 21:1;O8;HexNAc

C29H47NO13 (617.3047252)

ST 22:0;O7;HexNAc

C30H51NO12 (617.3411086000001)

ST 25:5;O5;HexNAc

C33H47NO10 (617.3199802)

ST 26:4;O4;HexNAc

C34H51NO9 (617.3563636)

ST 27:3;O3;HexNAc

C35H55NO8 (617.392747)

ST 28:2;O7;Tau

C30H51NO10S (617.3233506)

ST 29:1;O6;Tau

C31H55NO9S (617.359734)

Cyclo(RADfK)

C28H43N9O7 (617.3285288)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

n-(1-{10-benzyl-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl}-3-methyl-1-oxobutan-2-yl)-2-(dimethylamino)-3-methylpentanimidic acid

C35H47N5O5 (617.3577012)

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-1-oxo-3-phenylpropan-2-yl]-n,3-dimethyl-2-(methylamino)butanamide

C35H47N5O5 (617.3577012)

3-[(2s)-4-[(2e,4e,6s)-6-[(2s,5r,6r)-1,6-dimethyl-8,9-dioxaspiro[bicyclo[3.3.1]nonane-2,2'-oxiran]-3-en-7-yl]-4-methylhepta-2,4-dienoyl]-1-(5-hydroxy-6-methyloxan-2-yl)-3,5-dioxopyrrolidin-2-yl]propanoic acid; ethane

C33H47NO10 (617.3199802)

(1s,19s,22s,26r,31r)-2,22-dihydroxy-26-(2-hydroxypropan-2-yl)-1,9,9,11,11,31-hexamethyl-10,27-dioxa-3-azaheptacyclo[17.12.0.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹².0²²,³¹.0²³,²⁸]hentriaconta-2,4(16),5,7(12),14,23-hexaene-17,25-dione

C37H47NO7 (617.3352351999999)